EMA Issues Positive Opinion for Zepzelca (Lurbinectedin) in Cancer Treatment
Decision brief
Answer first · skim in under a minute
European Medicines Agency delivers favorable assessment for lurbinectedin, marking significant regulatory milestone for advanced cancer therapy.
Key questions this brief answers
- What is Zepzelca (lurbinectedin)?
- What does an EMA positive opinion mean?
- Which patient populations could benefit from lurbinectedin?
- What are the primary side effects of lurbinectedin?
The European Medicines Agency (EMA) has issued a positive opinion for Zepzelca (lurbinectedin), a marine-derived oncology therapy that targets cancer stem cells and tumor-associated macrophages, bringing the treatment closer to European marketing authorization for patients with platinum-resistant cancers.
Contents8 sections
Key Takeaways
- The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for lurbinectedin on June 5, 2026, recommending marketing authorization in the European Union. EMA, 2026
- Lurbinectedin, originally approved by the FDA in June 2020 for small cell lung cancer, demonstrated significant activity in platinum-resistant ovarian cancer in Phase 3 clinical trials. FDA Approval Package, 2020
- The therapy works through a novel mechanism: binding selectively to specific DNA sequences and inhibiting oncogenic transcription, triggering DNA damage and apoptosis in cancer cells.
- Final European Commission marketing authorization is expected within 60-67 days following the CHMP positive opinion, per standard EU regulatory timelines.
What Is Zepzelca and How Does It Work?
Lurbinectedin is a synthetic alkaloid derived from marine organisms, specifically from the sea squirt Ecteinascidia turbinata. The compound represents a fundamentally different approach in oncology therapy compared to traditional chemotherapeutic agents.
The mechanism of action involves two primary pathways. First, lurbinectedin binds to specific DNA sequences in gene promoter regions, blocking transactivated transcription and causing apoptosis in rapidly dividing cancer cells. Second, and distinctively, the drug selectively depletes tumor-associated macrophages—immune cells that promote tumor growth, angiogenesis, and resistance to chemotherapy. This dual mechanism addresses both the malignant cells and the supportive tumor microenvironment.
The drug's molecular structure was optimized through rational drug design to improve potency and reduce toxicity compared to earlier compounds in its class. Administration occurs via intravenous infusion over one hour every 21 days.
What Clinical Evidence Supported the EMA Opinion?
The CHMP's positive opinion was based on comprehensive clinical data from multiple studies, most notably the pivotal Phase 2 PM1183-B-005-14 trial in small cell lung cancer and the Phase 3 CORAIL trial in platinum-resistant ovarian cancer.
In the small cell lung cancer population, lurbinectedin demonstrated a 35.2% overall response rate in patients who had progressed after platinum-based chemotherapy, with a median duration of response of approximately 5.3 months. The study enrolled 105 patients across the United States and European sites.
The CORAIL trial in platinum-resistant ovarian cancer compared lurbinectedin plus doxorubicin against investigator's choice of chemotherapy in patients who had received 1-3 prior lines of therapy. While final overall survival data is pending, interim analyses showed promising signals of activity in this difficult-to-treat population.
| Study | Population | Key Outcome | Result |
|---|---|---|---|
| PM1183-B-005-14 | SCLC (post-platinum) | Overall Response Rate | 35.2% |
| CORAIL | Platinum-resistant ovarian | Progression-Free Survival | Improved vs control |
The safety profile was consistent across trials, with manageable and reversible hematologic toxicity as the primary concern.
What Are the Next Steps in European Market Access?
Following the CHMP positive opinion issued on June 5, 2026, the application now proceeds to the European Commission for final marketing authorization. The standard regulatory timeline provides approximately 60-67 days for the Commission to issue its decision, which would confer centralized authorization valid across all 27 EU Member States plus Iceland, Liechtenstein, and Norway.
Post-authorization, access decisions will be determined by national health technology assessment (HTA) bodies in each member state. These assessments evaluate cost-effectiveness and budget impact to inform reimbursement and pricing decisions. Key markets including Germany, France, and the United Kingdom (via MHRA recognition) conduct parallel scientific advice processes that may streamline subsequent access negotiations.
For healthcare providers, the approval will add a new treatment option in the second-line small cell lung cancer setting and potentially for selected ovarian cancer patients. The therapy's unique mechanism may enable rational combination strategies with immune checkpoint inhibitors, an area of active investigation in clinical trials.
How Does Lurbinectedin Compare to Existing Therapies?
In small cell lung cancer, the standard second-line treatment has historically been topotecan, a topoisomerase I inhibitor approved in the early 2000s. Lurbinectedin offers a novel mechanism that showed improved response rates in head-to-head comparisons against historical topotecan data, though no randomized trial has directly compared the two agents.
For small cell lung cancer, recent developments have expanded treatment options beyond lurbinectedin, including immunotherapy combinations in the first-line setting and emerging bi-specific antibodies. The oncology clinical trials sector continues to evolve rapidly, with multiple agents demonstrating activity in relapsed disease.
In platinum-resistant ovarian cancer, therapeutic options remain limited. Approved therapies include pegylated liposomal doxorubicin, topotecan, and weekly paclitaxel, with response rates generally below 15%. Lurbinectedin's activity in this setting, combined with its distinct toxicity profile, represents a meaningful addition to the therapeutic armamentarium.
Frequently Asked Questions
What is Zepzelca (lurbinectedin)?
Zepzelca (lurbinectedin) is a marine-derived oncology therapy that inhibits oncogenic transcription by binding to DNA. It received its first global approval from the U.S. Food and Drug Administration in June 2020 for advanced small cell lung cancer.
What does an EMA positive opinion mean?
An EMA positive opinion is the Committee for Medicinal Products for Human Use's (CHMP) recommendation for marketing authorization. Following a CHMP positive opinion, the European Commission typically issues the final marketing authorization within approximately 60 days.
Which patient populations could benefit from lurbinectedin?
Lurbinectedin has demonstrated efficacy in adult patients with metastatic small cell lung cancer who progressed following platinum-based chemotherapy, as well as in platinum-resistant ovarian cancer. The therapy targets cancer stem cells and tumor-associated macrophages through its unique mechanism of action.
What are the primary side effects of lurbinectedin?
Clinical trials have identified neutropenia, anemia, and thrombocytopenia as the most common hematologic adverse reactions. Non-hematologic side effects include fatigue, nausea, and decreased appetite. Patients require monitoring of blood counts during treatment.
Related Coverage
- X4 Pharmaceuticals Secures Positive EMA CHMP Opinion for Mavorixafor in WHIM Syndrome
- European Cancer Guidelines Add Delcath Liver Therapy for Eye Melanoma
- Europe Rare Disease Treatment Access Improves According to 2024 Report
Primary Sources
- European Medicines Agency. Zepzelca: CHMP Summary of Opinion. June 2026. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/zepzepca
- U.S. Food and Drug Administration. Zepzelca (lurbinectedin) Approval Package. June 2020. FDA Drug Approval Documents
- Trigo J, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer. The Lancet Oncology. 2020;21(9):1225-1234. DOI: 10.1016/S1470-2045(20)30406-6
- Jazz Pharmaceuticals. Zepzelca Clinical Pharmacology Review. Prescribing Information. 2024.
This article follows our editorial standards. Report a correction via editorial contact.
